297 related articles for article (PubMed ID: 24037953)
1. Cancer drug prices and the free-market forces.
Kantarjian H; Zwelling L
Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
[No Abstract] [Full Text] [Related]
2. Market spiral pricing of cancer drugs.
Light DW; Kantarjian H
Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
[No Abstract] [Full Text] [Related]
3. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
4. US hospitals object to changes in Genentech drug distribution.
Furlow B
Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290
[No Abstract] [Full Text] [Related]
5. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
6. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs.
Ramsey SD
Health Aff (Millwood); 2015 Apr; 34(4):571-5. PubMed ID: 25847638
[TBL] [Abstract][Full Text] [Related]
7. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
Kantarjian H; Mathisen MS; Lipton JH
JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
[No Abstract] [Full Text] [Related]
8. Cancer drugs in the United States: Justum Pretium--the just price.
Kantarjian HM; Fojo T; Mathisen M; Zwelling LA
J Clin Oncol; 2013 Oct; 31(28):3600-4. PubMed ID: 23650428
[No Abstract] [Full Text] [Related]
9. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
10. Cancer Drugs: An International Comparison of Postlicensing Price Inflation.
Savage P; Mahmoud S; Patel Y; Kantarjian H
J Oncol Pract; 2017 Jun; 13(6):e538-e542. PubMed ID: 28605615
[TBL] [Abstract][Full Text] [Related]
11. Cost of Cancer Drugs: Something Has To Give.
Bender E
Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
[TBL] [Abstract][Full Text] [Related]
12. [Cost/benefit analysis of cancer drugs].
Jordan B
Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical pricing. Let the market decide who gets discounts.
Mossinghoff GJ
Health Syst Rev; 1995; 28(1):24-5. PubMed ID: 10139754
[No Abstract] [Full Text] [Related]
14. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
Gordon N; Stemmer SM; Greenberg D; Goldstein DA
J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
[TBL] [Abstract][Full Text] [Related]
15. India spurns cancer patents.
Hayden EC
Nature; 2013 Aug; 500(7462):266. PubMed ID: 23955214
[No Abstract] [Full Text] [Related]
16. Pharmaceutical funding decisions must balance therapeutic innovation, opportunity costs and patient equity.
Ragupathy R; Jameson M
N Z Med J; 2016 Aug; 129(1440):22-4. PubMed ID: 27538036
[No Abstract] [Full Text] [Related]
17. Challenging the soaring price of cancer medicines: a call for equity and transparency.
Gonçalves A; Maraninchi D; Vernant JP
Ann Oncol; 2016 Sep; 27(9):1812-3. PubMed ID: 27154419
[No Abstract] [Full Text] [Related]
18. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
19. Cost to the NHS of Roche oncology treatments.
Atkins M
J R Soc Med; 2007 Jul; 100(7):303. PubMed ID: 17606744
[No Abstract] [Full Text] [Related]
20. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
